Lucosky Brookman is proud to have supported its client, HeartBeam Inc., a cardiac technology company, in successfully closing a secondary offering of 16,666,666 shares of common stock. This $25 million financing will enable HeartBeam to fund key clinical and regulatory milestones for its innovative 3D-vector electrocardiogram (VECG) platform, HeartBeam AIMIGo™, and prepare for its commercial launch in 2024.
